Related Experiment Videos
Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy
G P Midis1, Y Shen, L B Owen-Schaub
1Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA.
Cancer Research
|September 1, 1996
Summary
Soluble Fas (sFas) is elevated in cancer patients with solid tumors. This soluble form may play a role in disease progression and can be found in both serum and tumors.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Fas is a cell surface receptor that triggers apoptosis.
- Soluble Fas (sFas), derived from alternative mRNA splicing, can inhibit cell-surface Fas.
- The role of sFas in solid tumors is not well understood.
Purpose of the Study:
- To investigate the presence and levels of soluble Fas (sFas) in patients with nonhematopoietic solid tumors.
- To determine if sFas levels correlate with disease stage and tumor burden.
- To explore the systemic and local release of sFas in the tumor microenvironment.
Main Methods:
- Utilized a Fas-specific ELISA and immunoprecipitation techniques.
- Analyzed serum and tumor explant samples from 104 cancer patients.
- Quantified the 40-42 kDa sFas species.
Main Results:
- Demonstrated elevated levels of a 40-42 kDa sFas species in both patient serum and tumor explants.
- Showed that sFas levels increase with disease stage and tumor burden.
- Provided evidence for both systemic and local synthesis and release of sFas.
Conclusions:
- This study presents the first evidence of increased sFas in patients with solid tumors.
- Elevated sFas levels correlate with disease progression, suggesting a potential role in cancer.
- sFas is produced and released both in the bloodstream and within the tumor microenvironment.